| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
* Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710
Center for Translational Medicine, Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania 19107
Heart failure represents the endpoint to many triggering cardiovascular pathologies. However, there are molecular and biochemical features that remain common to the failing heart, despite the varying etiologies. Principal among these is heightened activation of the sympathetic nervous system and associated enhancement of adrenergic signaling pathways via the catecholamines, norepinephrine and epinephrine. During heart failure, several hallmark alterations in the adrenergic system contribute to loss of cardiac function. To specifically study these changes in a physiologically relevant setting, we and others have utilized advances in genetically engineered mouse technology. This chapter will discuss the many transgenic and knockout mouse models that have been developed to study the adrenergic system in the normal and failing heart. These models include genetically manipulated alterations of adrenergic receptors, linked heterotrimeric G proteins, and the regulatory G protein-coupled receptor kinases (GRKs). Among the more-interesting information gained from these models is the finding that inhibition of a particular GRK — GRK2 or ß adrenergic receptor kinase 1 (ßARK1) — is a potential novel therapeutic strategy to improve function in the setting of heart failure. Furthermore, we will discuss recent transgenic research that proposes an important role for hypertension in the development of heart failure. Overall, genetically engineered mouse models pertaining to this critical myocardial signaling system have provided novel insight into heart function under normal conditions and during states of dysfunction and failure.
This article has been cited by other articles:
 |
|
 |
|
  H. I. Cohn, D. M. Harris, S. Pesant, M. Pfeiffer, R.-H. Zhou, W. J. Koch, G. W. Dorn 2nd, and A. D. Eckhart Inhibition of vascular smooth muscle G protein-coupled receptor kinase 2 enhances {alpha}1D-adrenergic receptor constriction Am J Physiol Heart Circ Physiol, October 1, 2008; 295(4): H1695 - H1704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kang, K. Y. Chung, and J. W. Walker G-Protein Coupled Receptor Signaling in Myocardium: Not for the Faint of Heart Physiology, June 1, 2007; 22(3): 174 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Reppe, L. Stilgren, B. Abrahamsen, O. K. Olstad, F. Cero, K. Brixen, L. S. Nissen-Meyer, and K. M. Gautvik Abnormal muscle and hematopoietic gene expression may be important for clinical morbidity in primary hyperparathyroidism Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1465 - E1473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Mueller, S. A. Grandy, and S. E. Howlett Protein Kinase A-Mediated Phosphorylation Contributes to Enhanced Contraction Observed in Mice That Overexpress beta-Adrenergic Receptor Kinase-1 J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1307 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Liggett Lymphocyte GRK levels as biomarkers in heart failure Eur. Heart J., September 1, 2005; 26(17): 1695 - 1696. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. MacDonnell, H. Kubo, D. L. Crabbe, B. F. Renna, P. O. Reger, J. Mohara, L. A. Smithwick, W. J. Koch, S. R. Houser, and J. R. Libonati Improved Myocardial {beta}-Adrenergic Responsiveness and Signaling With Exercise Training in Hypertension Circulation, June 28, 2005; 111(25): 3420 - 3428. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
